Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Outsourcing

4,186.891
-83.308-1.95%
Number of Gainers:2
Number of Losers:6
Number of Flat:- -
PE:- -
High:4,380.011
Open:4,306.312
Low:4,148.680
Close:4,270.199
Volume:152.21M
Turnover:7.72B
Market Cap:994.30B
Float Cap:410.22B

Loading ...

VIVA Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

THOMSON REUTERS
·
Yesterday

VIVA Biotech H1 Profit Falls on Weaker Investment Income, FX Headwinds

Reuters
·
Yesterday

VIVA Biotech - Does not Recommend the Distribution of an Interim Dividend for Hy

THOMSON REUTERS
·
Yesterday

Viva Biotech FY26 H1 Net Profit Falls 32.1% to RMB 100.9 Million; Revenue Rises 21% to RMB 1.01 Billion

Reuters
·
Yesterday

VIVA Biotech Holdings H1 Revenue RMB 1,006.5 Million

THOMSON REUTERS
·
Yesterday

JPMorgan Chase & Co.'S Long Position in H-Shares of WuXi AppTec Co., Ltd. Increases to 12.09% on August 21 from 10.82% - HKEX

THOMSON REUTERS
·
Yesterday

JPMorgan Boosts Stake in Pharmaron with HK$137 Million Share Purchase

Deep News
·
Yesterday

WuXi Biologics (Cayman) (SEHK:2269) Shares Climbed, So What Is Driving Attention Now?

Simply Wall St.
·
Yesterday

WuXi XDC Grants 342,300 Restricted Shares to Employees Under 2024 Share Scheme

Reuters
·
Aug 25

WuXi Biologics Reports Strong Profitable Growth in H1 2026

THOMSON REUTERS
·
Aug 25

Wuxi Bio's Interim Results Exceed Expectations and Break Broker Targets, with Accelerated Manufacturing Growth Reinforcing Long-Term Investment Thesis

Stock News
·
Aug 25

Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Stock News
·
Aug 25

WuXi Biologics Posts Higher Adjusted Attributable Profit in H1

MT Newswires Live
·
Aug 25

WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln

Reuters
·
Aug 25

WUXI BIO reports 4.3% rise in interim net profit to RMB 2.44 billion

Stock News
·
Aug 25

WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion

Reuters
·
Aug 25

WuXi Biologics H1 Net Income Attributable RMB 2,439.8 Million

THOMSON REUTERS
·
Aug 25

WuXi AppTec (4800亿市值) Faces Cybersecurity Breach; Global Drugmakers Report Recent Hacks

Deep News
·
Aug 25

Wuxi Biologics (Cayman) Stock Rallies 7.4% in Hong Kong

Dow Jones
·
Aug 25

Midday Market Snapshot: Hang Seng Index Slips 0.25% in Morning Session, Mainland Property Stocks Rally Broadly

Stock News
·
Aug 25